CU20190100A7 - Anticuerpos biespecíficos y método de fabricación de los mismos - Google Patents

Anticuerpos biespecíficos y método de fabricación de los mismos

Info

Publication number
CU20190100A7
CU20190100A7 CU2019000100A CU20190100A CU20190100A7 CU 20190100 A7 CU20190100 A7 CU 20190100A7 CU 2019000100 A CU2019000100 A CU 2019000100A CU 20190100 A CU20190100 A CU 20190100A CU 20190100 A7 CU20190100 A7 CU 20190100A7
Authority
CU
Cuba
Prior art keywords
manufacturing
specific antibodies
monoclonal antibodies
antibodies
bbmab
Prior art date
Application number
CU2019000100A
Other languages
English (en)
Inventor
Michael Otto Bardroff
Tina Buch
Christian Graf
Daniel Heitmann
Thomas Jostock
Hans-Peter Knopf
Rolf Koheler
Jiri Kovarik
Stephen John Oliver
Dhavalkumar Patel
Maximilian Woisetschlaeger
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CU20190100A7 publication Critical patent/CU20190100A7/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

<p>La invención se refiere a anticuerpos monoclonales biespecíficos bivalentes (bbmAb) o sus variantes, y a métodos de fabricación de dichos anticuerpos mediante la coexpresión de derivados mutados Fc modificados, de dos anticuerpos monoclonales diferentes, en líneas celulares de mamíferos.</p>
CU2019000100A 2017-06-12 2018-06-08 Anticuerpos biespecíficos y método de fabricación de los mismos CU20190100A7 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762518090P 2017-06-12 2017-06-12
PCT/IB2018/054140 WO2018229612A1 (en) 2017-06-12 2018-06-08 Method of manufacturing bispecific antibodies, bispecific antibodies and therapeutic use of such antibodies

Publications (1)

Publication Number Publication Date
CU20190100A7 true CU20190100A7 (es) 2020-11-30

Family

ID=62948274

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2019000100A CU20190100A7 (es) 2017-06-12 2018-06-08 Anticuerpos biespecíficos y método de fabricación de los mismos

Country Status (25)

Country Link
US (2) US20190002589A1 (es)
EP (1) EP3638692A1 (es)
JP (2) JP7106234B2 (es)
KR (2) KR20200005746A (es)
CN (1) CN110730788A (es)
AR (1) AR112419A1 (es)
AU (2) AU2018284303B2 (es)
BR (1) BR112019025904A2 (es)
CA (1) CA3061097A1 (es)
CL (1) CL2019003613A1 (es)
CO (1) CO2019013838A2 (es)
CR (1) CR20190558A (es)
CU (1) CU20190100A7 (es)
EA (1) EA201992670A1 (es)
EC (1) ECSP19087580A (es)
IL (1) IL271179B1 (es)
JO (1) JOP20190283B1 (es)
MA (1) MA49394A (es)
MX (1) MX2019015021A (es)
PE (1) PE20200384A1 (es)
SG (1) SG10201913536TA (es)
TW (1) TWI826377B (es)
UY (1) UY37758A (es)
WO (1) WO2018229612A1 (es)
ZA (1) ZA201906757B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
JOP20200308A1 (ar) * 2012-09-07 2017-06-16 Novartis Ag جزيئات إرتباط il-18
US9914785B2 (en) 2012-11-28 2018-03-13 Zymeworks Inc. Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
US9725710B2 (en) 2014-01-08 2017-08-08 Flodesign Sonics, Inc. Acoustophoresis device with dual acoustophoretic chamber
CN110658340B (zh) * 2015-01-08 2023-10-31 苏州康宁杰瑞生物科技有限公司 具有共同轻链的双特异性抗体或抗体混合物
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
EP3359576A4 (en) 2015-10-08 2019-08-28 Zymeworks Inc. ANTIGENBINDING POLYPEPTIDE CONSTRUCTS WITH KAPPA AND LAMBDA LIGHT CHAINS AND USES THEREOF
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
UY37758A (es) 2017-06-12 2019-01-31 Novartis Ag Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos
WO2019118921A1 (en) 2017-12-14 2019-06-20 Flodesign Sonics, Inc. Acoustic transducer drive and controller
CN112584857A (zh) * 2018-05-09 2021-03-30 诺华股份有限公司 卡那吉努单抗的用途
CN111018969A (zh) * 2019-12-27 2020-04-17 上海药明生物技术有限公司 采用轻链select联合层析色谱纯化双特异性抗体的方法
CN115066258A (zh) * 2020-02-28 2022-09-16 上海药明生物技术有限公司 双特异性抗体的纯化
KR20230100732A (ko) * 2020-11-04 2023-07-05 제넨테크, 인크. 항-cd20/항-cd3 이중특이성 항체의 피하 투여
TW202233237A (zh) * 2020-11-18 2022-09-01 瑞士商諾華公司 用於在治療ｎｌｒｃ４－ｇｏｆ炎性體病變中使用的雙特異性抗體
US20240294626A1 (en) * 2021-06-22 2024-09-05 Novartis Ag Bispecific antibodies for use in treatment of hidradenitis suppurativa
CN113980135B (zh) * 2021-12-27 2022-04-19 三优生物医药(上海)有限公司 一种结合冠状病毒双特异性抗体的抗药抗体及其制备方法和应用
AR129136A1 (es) * 2022-04-26 2024-07-17 Novartis Ag Anticuerpos multiespecíficos que se dirigen a il-13 e il-18

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
GB8725529D0 (en) 1987-10-30 1987-12-02 Delta Biotechnology Ltd Polypeptides
ATE135370T1 (de) 1988-12-22 1996-03-15 Kirin Amgen Inc Chemisch modifizierte granulocytenkolonie erregender faktor
US5582996A (en) 1990-12-04 1996-12-10 The Wistar Institute Of Anatomy & Biology Bifunctional antibodies and method of preparing same
WO1993006213A1 (en) 1991-09-23 1993-04-01 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
US5910573A (en) 1992-01-23 1999-06-08 Merck Patent Gesellschaft Mit Beschrankter Haftung Monomeric and dimeric antibody-fragment fusion proteins
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
AU4116793A (en) 1992-04-24 1993-11-29 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
CA2163345A1 (en) 1993-06-16 1994-12-22 Susan Adrienne Morgan Antibodies
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US20030148463A1 (en) 1997-04-14 2003-08-07 Micromet Ag Novel method for the production of anti-human antigen receptors and uses thereof
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
DK2180007T4 (da) 1998-04-20 2017-11-27 Roche Glycart Ag Glycosyleringsteknik for antistoffer til forbedring af antistofafhængig cellecytotoxicitet
KR20060067983A (ko) 1999-01-15 2006-06-20 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
EP2275541B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
WO2002000879A2 (en) 2000-06-28 2002-01-03 Glycofi, Inc. Methods for producing modified glycoproteins
GB0020685D0 (en) 2000-08-22 2000-10-11 Novartis Ag Organic compounds
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
AU2002337935B2 (en) 2001-10-25 2008-05-01 Genentech, Inc. Glycoprotein compositions
CA2965865C (en) 2002-07-18 2021-10-19 Merus N.V. Recombinant production of mixtures of antibodies
MX2007002856A (es) 2004-09-02 2007-09-25 Genentech Inc Metodos para el uso de ligandos receptores de muerte y anticuerpos c20.
EP3050963B1 (en) 2005-03-31 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
ES2944067T3 (es) 2005-10-26 2023-06-19 Novartis Ag Uso de anticuerpos anti il-1beta
KR20110079922A (ko) * 2006-04-14 2011-07-11 노파르티스 아게 안과 장애 치료를 위한 ｉｌ－1 항체의 용도
EP2626372B1 (en) 2007-03-29 2018-03-21 Genmab A/S Bispecific antibodies and methods for production thereof
CA3213888A1 (en) * 2007-05-29 2008-12-04 Novartis Ag New indications for anti-il-i-beta therapy
PT2227546T (pt) 2007-12-21 2016-08-12 Novartis Ag Vector de expressão em mamíferos
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
HUE028536T2 (en) 2008-01-07 2016-12-28 Amgen Inc Method for producing antibody to FC heterodimer molecules using electrostatic control effects
UY31861A (es) 2008-06-03 2010-01-05 Abbott Lab Inmunoglobulina con dominio variable dual y usos de la misma
WO2010006060A2 (en) 2008-07-08 2010-01-14 Abbott Laboratories Prostaglandin e2 dual variable domain immunoglobulins and uses thereof
JP5788796B2 (ja) 2008-08-28 2015-10-07 ノバルティス アーゲー 終止コドンのリードスルーによるポリペプチドアイソフォームの細胞表面提示
BRPI1008762B8 (pt) 2009-02-27 2021-05-25 Novartis Ag métodos para seleção de células de mamífero expressando uma proteína heteróloga, para produzir um produto de interesse e uso de um meio de cultura seletivo
DK2401377T3 (en) 2009-02-27 2016-08-29 Novartis Ag Expression vector system comprising two selection markers
WO2011116387A1 (en) * 2010-03-19 2011-09-22 Tetragenetics, Inc. Production of aglycosylated monoclonal antibodies in ciliates
PT2560993T (pt) 2010-04-20 2024-09-16 Genmab As Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas
MX338953B (es) 2010-08-16 2016-05-06 Novimmune Sa Metodos para la generacion de anticuerpos multiespecificos y multivalentes.
AU2012227883A1 (en) 2011-03-17 2013-10-24 Ramot At Tel-Aviv University Ltd. Bi- and monospecific, asymmetric antibodies and methods of generating the same
TWI838039B (zh) 2011-03-28 2024-04-01 法商賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
EP3674320A3 (en) 2011-10-27 2020-08-12 Genmab A/S Production of heterodimeric proteins
SI2794905T1 (sl) * 2011-12-20 2020-08-31 Medimmune, Llc Modificirani polipeptidi za ogrodja bispecifičnega protitelesa
JOP20200308A1 (ar) 2012-09-07 2017-06-16 Novartis Ag جزيئات إرتباط il-18
WO2014052072A1 (en) 2012-09-26 2014-04-03 3M Innovative Properties Company Coatable composition, soil-resistant composition, soil-resistant articles, and methods of making the same
US10738132B2 (en) 2013-01-14 2020-08-11 Xencor, Inc. Heterodimeric proteins
WO2014131711A1 (en) 2013-02-26 2014-09-04 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
CN105377889B (zh) 2013-03-15 2020-07-17 Xencor股份有限公司 异二聚体蛋白
AU2014233528B2 (en) * 2013-03-15 2019-02-28 Abbvie Biotherapeutics Inc. Fc variants
NZ710929A (en) 2013-03-15 2018-02-23 Novartis Ag Antibody drug conjugates
KR102288857B1 (ko) 2013-12-20 2021-08-11 노파르티스 아게 신규한 진핵 세포 및 관심 생성물의 재조합 발현 방법
DK3083677T3 (da) 2013-12-20 2019-11-25 Novartis Ag Hidtil ukendte eukaryote celler og fremgangsmåder til rekombinant ekspression af et produkt af interesse
US20170002060A1 (en) * 2014-01-08 2017-01-05 Moderna Therapeutics, Inc. Polynucleotides for the in vivo production of antibodies
WO2015198240A2 (en) 2014-06-25 2015-12-30 Novartis Ag Compositions and methods for long acting proteins
GB201414823D0 (en) * 2014-08-20 2014-10-01 Argen X Bv Multispecific antibodies
CN110894240B (zh) 2014-11-26 2022-04-15 森科股份有限公司 结合cd3和肿瘤抗原的异二聚体抗体
AU2015353416C1 (en) 2014-11-26 2022-01-27 Xencor, Inc. Heterodimeric antibodies that bind CD3 and CD38
US20160176969A1 (en) 2014-11-26 2016-06-23 Xencor, Inc. Heterodimeric antibodies including binding to cd8
WO2016105450A2 (en) 2014-12-22 2016-06-30 Xencor, Inc. Trispecific antibodies
AU2016225968B2 (en) 2015-03-05 2020-07-23 Think Surgical, Inc. Methods for locating and tracking a tool axis
SG11201708620QA (en) 2015-05-08 2017-11-29 Xencor Inc Heterodimeric antibodies that bind cd3 and tumor antigens
WO2017011773A2 (en) * 2015-07-15 2017-01-19 Modernatx, Inc. Codon-optimized nucleic acids encoding antibodies
EP3359576A4 (en) * 2015-10-08 2019-08-28 Zymeworks Inc. ANTIGENBINDING POLYPEPTIDE CONSTRUCTS WITH KAPPA AND LAMBDA LIGHT CHAINS AND USES THEREOF
JP7195929B2 (ja) * 2016-04-13 2022-12-26 サノフイ 三重特異性および／または三価結合タンパク質
WO2018057955A1 (en) * 2016-09-23 2018-03-29 Elstar Therapeutics, Inc. Multispecific antibody molecules comprising lambda and kappa light chains
UY37758A (es) 2017-06-12 2019-01-31 Novartis Ag Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos

Also Published As

Publication number Publication date
CR20190558A (es) 2020-01-28
AU2021206810A1 (en) 2021-08-12
CL2019003613A1 (es) 2020-07-03
TW201906864A (zh) 2019-02-16
JOP20190283B1 (ar) 2023-09-17
WO2018229612A1 (en) 2018-12-20
MX2019015021A (es) 2020-02-24
JP2022116038A (ja) 2022-08-09
CN110730788A (zh) 2020-01-24
UY37758A (es) 2019-01-31
JOP20190283A1 (ar) 2019-12-05
ECSP19087580A (es) 2019-12-27
RU2019140335A (ru) 2021-07-13
MA49394A (fr) 2020-04-22
IL271179A (en) 2020-01-30
EA201992670A1 (ru) 2020-07-08
AU2018284303B2 (en) 2021-04-22
RU2019140335A3 (es) 2021-10-04
JP7106234B2 (ja) 2022-07-26
AU2018284303A1 (en) 2019-11-07
KR20200005746A (ko) 2020-01-16
US20190002589A1 (en) 2019-01-03
JP2020524991A (ja) 2020-08-27
SG10201913536TA (en) 2020-02-27
AR112419A1 (es) 2019-10-30
EP3638692A1 (en) 2020-04-22
KR102633368B1 (ko) 2024-02-06
KR20220167340A (ko) 2022-12-20
ZA201906757B (en) 2023-03-29
TWI826377B (zh) 2023-12-21
BR112019025904A2 (pt) 2020-06-30
CO2019013838A2 (es) 2020-05-29
PE20200384A1 (es) 2020-02-24
US11987644B2 (en) 2024-05-21
CA3061097A1 (en) 2018-12-20
US20200308309A1 (en) 2020-10-01
IL271179B1 (en) 2024-08-01

Similar Documents

Publication Publication Date Title
CU20190100A7 (es) Anticuerpos biespecíficos y método de fabricación de los mismos
CL2020003127A1 (es) Anticuerpos bispecificos anti-pvrig/anti-tigit y métodos de uso
CY1124691T1 (el) Διειδικα αντισωματα ειδικα για pd1 και τιμ3
CO2018000710A2 (es) Anticuerpos biespecíficos específicos para un receptor de tnf coestimulador
CL2019002824A1 (es) Anticuerpos anti-lag3.
CL2018000461A1 (es) Anticuerpos biespecíficos con tetravalencia para un receptor de fnt coestimulador.
CL2019002521A1 (es) Método para producir anticuerpos multiespecíficos.
EA202090812A1 (ru) Новые биспецифические полипептидные комплексы
MA55363A (fr) Anticorps multispécifiques egfr x cd28
BR112019007288A2 (pt) proteína heterodimérica biespecífica, composições de ácido nucleico e de vetor de expressão, vetor de expressão, célula hospedeira, e, métodos para produzir proteína heterodimérica biespecífica e para tratar câncer em um paciente
MX2016003593A (es) Anticuerpos de cadena ligera variable comun intercambiada de dominio multiespecifico.
EA202090931A3 (ru) Композиции и способы перепрограммирования tcr с помощью гибридных белков
BR112016014022A2 (pt) anticorpos anti-cd3, ácido nucleico isolado, vetor, célula hospedeira, método de produção do anticorpo anti-cd3, imunoconjugado, composição, uso do anticorpo anti-cd3, métodos de tratamento, métodos de intensificação da função imune e kit
AR114283A1 (es) Receptores quiméricos de dll3 y métodos para su uso
MA54539A (fr) Anticorps anti-muc16 x anti-cd28 bispécifiques et leurs utilisations
CL2020002540A1 (es) Anticuerpos anti-hla-g y utilización de los mismos
EA201891709A1 (ru) Антигенсвязывающие белки, связывающие pd-l1
EA201990894A1 (ru) Анти-pd-1/анти-her2 гетеродимерное биспецифическое антитело со структурой природного антитела и способ его получения
EA201691321A1 (ru) Антитела и способы их применения
AR096839A1 (es) Proceso mejorado para la producción de anticuerpos monoclonales
JOP20190246A1 (ar) جسم مضاد أحادي النسيلة لـ pd-l1
EA201790587A1 (ru) Геопозиционирование с использованием направляемых поверхностных волн
DK3797121T3 (da) Antistoffer, der er specifikke for CD3, og anvendelser deraf
EA201892096A1 (ru) Нейтрализующие моноклональные антитела к il-25 и их применение
PL439808A1 (pl) Sposoby i kompozycje hodowli komórkowych do produkcji przeciwciał